About L & C Bio
L & C Bio is a publicly listed company based in Seongnam-si (South Korea) founded in 2011. Developer of allograft and xenograft technologies. The company has 135 employees. Its website lncbio.co.kr draws about 35 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools and Diversified.
Company details
L C Bio was founded in 2011 and is based in Seongnam-si, South Korea. Allograft and xenograft solutions are developed across tissue engineering, medical devices, and cosmeceuticals. Manufacturing facilities are certified under ISO 9001 and GMP standards. Biomaterials for tissue repair, collagen-based supplements, implantable biomaterial bones, deep wound coverings, and bioabsorbable wound materials are produced. Operations focus on biomedical innovations for implantation and repair applications.
- Headquarters Seongnam-si, South Korea
- Employees 135
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website lncbio.co.kr
- Legal Name L&C Bio Co., Ltd.
- Annual Revenue$59.19 M (USD)18.66as on Dec 31, 2025
- Net Profit-$95.67 M (USD)-197.58as on Dec 31, 2025
- EBITDA$8.01 M (USD)15.1as on Dec 31, 2025
- Employee Count135
IPO & Listings of L & C Bio
L & C Bio is a publicly listed company on the KRX with ticker symbol 290650 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Oct 2018
- Listed onKRX: 290650
- Listed entityL&C BIO Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7290650001
- Share price60,300.00 KRW (+3.61% on the day) · 2026-10-14
- Market capitalisation1,780,669,921,875.00 KRW
- EPS (diluted, trailing year)-6,013.46 KRW
- Dividend yield0.08%
- Volume (last session)717,835
Financials of L & C Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 85.48B KRW | -138.17B KRW | 11.57B KRW |
| 2024 | 72.03B KRW | 141.60B KRW | 10.05B KRW |
| 2023 | 65.93B KRW | 48.36B KRW | 12.70B KRW |
| 2022 | 52.57B KRW | 4.54B KRW | 13.68B KRW |
| 2021 | 45.68B KRW | 13.81B KRW | 16.07B KRW |
Detailed financial statements for L & C Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of L & C Bio
The website of L & C Bio (lncbio.co.kr) receives about 35.1K visits a month.
- Monthly visits35.1K
Websites whose visitors overlap most with L & C Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thebionews.net | thebionews.net | 100% | #353,035 | – | |
bosa.co.kr | bosa.co.kr | 89% | #127,846 | – | |
yakup.com | yakup.com | 85% | #118,603 | – | |
dailymedi.com | dailymedi.com | 84% | #145,758 | – | |
| hitnews.co.kr | 84% | #146,502 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for L & C Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about L & C Bio
Complete news archive for L C Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about L & C Bio
L & C Bio was founded in 2011.
L & C Bio is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
L & C Bio has 135 employees.
Annual revenue of L & C Bio is $59.19M as on Dec 31, 2025.
L C Bio was founded in 2011 and is based in Seongnam-si, South Korea. Allograft and xenograft solutions are developed across tissue engineering, medical devices, and cosmeceuticals. Manufacturing facilities are certified under ISO 9001 and GMP standards. Biomaterials for tissue repair, collagen-based supplements, implantable biomaterial bones, deep wound coverings, and bioabsorbable wound materials are produced. Operations focus on biomedical innovations for implantation and repair applications.
Yes, L & C Bio is publicly traded on KRX under the ticker symbol 290650.